Compounds > 3,3',4,5'-tetrahydroxystilbene
Page last updated: 2024-08-16

3,3',4,5'-tetrahydroxystilbene and Multiple Myeloma

3,3',4,5'-tetrahydroxystilbene has been researched along with Multiple Myeloma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Endo, T; Kim, Y; Lu, D; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG1
Kim, Y; Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG1
Alas, S; Bonavida, B1

Other Studies

3 other study(ies) available for 3,3',4,5'-tetrahydroxystilbene and Multiple Myeloma

ArticleYear
Targeting the Wnt/beta-catenin pathway in multiple myeloma.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Animals; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Blotting, Western; Cell Proliferation; Cells, Cultured; Ciclopirox; Colon; Diuretics; Drug Synergism; Ethacrynic Acid; Flow Cytometry; Humans; Mice; Multiple Myeloma; Protein-Tyrosine Kinases; Pyridones; Stilbenes; Wnt Proteins

2013
Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
    Hematological oncology, 2014, Volume: 32, Issue:4

    Topics: Animals; Apoptosis; beta Catenin; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fibroblasts; Humans; Immunotherapy; Inhibitory Concentration 50; Mice; Multiple Myeloma; Propidium; Stilbenes; Treatment Outcome; Wnt Proteins; Wnt Signaling Pathway

2014
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cytokines; DNA Fragmentation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Humans; Immunoblotting; Interleukin-10; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Lymphoma, Non-Hodgkin; Models, Biological; Multiple Myeloma; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; STAT3 Transcription Factor; Stilbenes; Time Factors; Trans-Activators; Tumor Cells, Cultured; Tyrphostins; Vinblastine

2003